Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

医学 内科学 放化疗 头颈部 肿瘤科 基底细胞 顺铂 头颈部癌 头颈部鳞状细胞癌 放射治疗 化疗 外科 总体生存率
作者
Xu-Shan Sun,Yungan Tao,Christophe Le Tourneau,Y. Pointreau,Christian Sire,Marie‐Christine Kaminsky,Alexandre Coutté,M. Alfonsi,Pierre Boisselier,Laurent Martin,J. Miroir,Jean‐François Ramée,Jean‐Pierre Delord,Florian Clatot,Frédéric Rolland,Julie Villa,Nicolas Magné,Olgun Eliçin,Elisabeta Gherga,F. Nguyen,C. Lafond,G. Béra,Valentin Calugaru,Lionnel Geoffrois,Bruno Chauffert,Angela Zubel,Claudio Zanna,S. Brienza,Philippa Crompton,Elisabeth Rouits,Kathrin Gollmer,Sergio Szyldergemajn,Jean Bourhis
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (9): 1173-1187 被引量:100
标识
DOI:10.1016/s1470-2045(20)30327-2
摘要

Background Debio 1143 is an orally available antagonist of inhibitor of apoptosis proteins with the potential to enhance the antitumour activity of cisplatin and radiotherapy. The radiosensitising effect of Debio 1143 is mediated through caspase activation and TNF, IFNγ, CD8 T cell-dependent pathways. We aimed to investigate the efficacy and safety of Debio 1143 in combination with standard chemoradiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. Methods This double-blind, multicentre, randomised, phase 2 study by the French Head and Neck Radiotherapy Oncology Group (GORTEC) was run at 19 hospitals in France and Switzerland. Eligible patients were aged 18–75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0–3, and M0] disease), Eastern Cooperative Oncology Group performance status of 0 or 1, a history of heavy tobacco smoking (>10 pack-years) with no previous or current treatment for invasive head and neck cancer, and no previous treatment with inhibitor of apoptosis protein antagonists. Patients were randomly assigned (1:1) to receive oral Debio 1143 (200 mg per day on days 1–14 of 21-day cycles, for three cycles) or oral placebo (20 mg/mL, administered at the same dosing schedule) using a stochastic minimisation technique according to node involvement and primary tumour site, and HPV-16 status in patients with an oropharyngeal primary tumour site. All patients received standard high-dose cisplatin chemoradiotherapy. The primary endpoint was the proportion of patients with locoregional control 18 months after chemoradiotherapy, analysed in the intention-to-treat population (primary analysis), and repeated in the per-protocol population. Responses were assessed according to Response Evaluation Criteria in Solid Tumors (version 1.1). This trial is registered with ClinicalTrials.gov, NCT02022098, and is still active but not recruiting. Findings Between Jan 25, 2016, and April 24, 2017, 48 patients were randomly assigned to the Debio 1143 group and 48 to the placebo group (one patient in the placebo group did not receive the study drug and was not included in the safety analysis). Median duration of follow-up was 25·0 months (IQR 19·6–29·4) in the Debio 1143 group and 24·2 months (6·6–26·8) in the placebo group. Locoregional control 18 months after chemoradiotherapy was achieved in 26 (54%; 95% CI 39–69) of 48 patients in the Debio 1143 group versus 16 (33%; 20–48) of 48 patients in the placebo group (odds ratio 2·69 [95% CI 1·13–6·42], p=0·026). Grade 3 or worse adverse events were reported in 41 (85%) of 48 patients in the Debio 1143 group and in 41 (87%) of 47 patients in the placebo group. The most common grade 3–4 adverse events were dysphagia (in 24 [50%] patients in the Debio 1143 group vs ten [21%] in the placebo group), mucositis (in 15 [31%] vs ten [21%]), and anaemia (in 17 [35%] vs 11 [23%]). Serious treatment-emergent adverse events were recorded in 30 (63%) of 48 patients in the Debio 1143 group and 28 (60%) of 47 in the placebo group. In the placebo group, two (4%) deaths were due to adverse events (one multiple organ failure and one asphyxia; neither was considered to be related to treatment). No deaths due to adverse events occurred in the Debio 1143 group. Interpretation To our knowledge, this is the first treatment regimen to achieve superior efficacy in this disease setting against a high-dose cisplatin chemoradiotherapy comparator in a randomised trial. These findings suggest that inhibition of inhibitor of apoptosis proteins is a novel and promising approach in this poor prognostic population and warrant confirmation in a phase 3 study with the aim of expanding the therapeutic options for these patients. Funding Debiopharm.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
3秒前
韭菜盒子发布了新的文献求助10
5秒前
潘特发布了新的文献求助10
8秒前
乌滴子完成签到,获得积分10
9秒前
量子星尘发布了新的文献求助10
10秒前
善学以致用应助韭菜盒子采纳,获得10
10秒前
jiaaniu完成签到 ,获得积分10
12秒前
清脆靳完成签到,获得积分10
13秒前
cp3xzh完成签到,获得积分10
13秒前
tian发布了新的文献求助10
15秒前
tian发布了新的文献求助10
15秒前
明理宛秋完成签到 ,获得积分10
16秒前
S月小小完成签到,获得积分10
20秒前
斯文的慕儿完成签到 ,获得积分10
27秒前
keen完成签到 ,获得积分10
27秒前
韭菜盒子完成签到,获得积分20
28秒前
潘特完成签到,获得积分10
29秒前
小彭友完成签到,获得积分10
40秒前
41秒前
josie完成签到 ,获得积分10
45秒前
llll完成签到 ,获得积分10
45秒前
量子星尘发布了新的文献求助10
45秒前
韭菜发布了新的文献求助10
45秒前
外向的斑马完成签到 ,获得积分10
46秒前
村长热爱美丽完成签到 ,获得积分10
48秒前
尹尹关注了科研通微信公众号
50秒前
呆呆完成签到 ,获得积分10
51秒前
xianyaoz完成签到 ,获得积分0
58秒前
杨远杰完成签到,获得积分10
59秒前
蓝桉完成签到 ,获得积分10
59秒前
JuliaWang完成签到 ,获得积分10
1分钟前
无限的含羞草完成签到,获得积分10
1分钟前
八二力完成签到 ,获得积分10
1分钟前
韭菜发布了新的文献求助10
1分钟前
情怀应助科研通管家采纳,获得30
1分钟前
water应助科研通管家采纳,获得10
1分钟前
JamesPei应助科研通管家采纳,获得10
1分钟前
2012csc完成签到 ,获得积分0
1分钟前
风清扬应助韭菜采纳,获得10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022